Cellular Processing Core (CPC)The CPC has been established to provide the rapid and safe transition of basic research ideas to clinicalpractice. Some of the preclinical tasks include the qualification and testing of reagents, scale-up of methods,development of Standard Operating Procedures (SOPs), ongoing process validation, the provision of acontrolled good tissue practice GTP infrastructure and support for compiling Investigational New Drug(IND)applications; The CPC will support all 4 Projects in conduct of the clinical trials and will support Project 2 inthe translation of the research studies proposed in this project to develop clinical trials. This is a rate limitingstep at many Institutes and by centralizing this function in the Core, these studies will undergo pre clinicaldevelopment and scale up in an optimal fashion. The personnel in the CPC will assist the PI of Project 2 insubmitting an IND to conduct the clinical trial. The Core will provide all Projects with QA/QC assistance andassist with development of SOPs and worksheets to ensure compliance with regulatory agents in theconduct of the clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA015396-32A1
Application #
7271677
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Project Start
2007-04-01
Project End
2012-02-28
Budget Start
2007-04-05
Budget End
2008-02-29
Support Year
32
Fiscal Year
2007
Total Cost
$442,231
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Kasamon, Yvette L; Fuchs, Ephraim J; Zahurak, Marianna et al. (2018) Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant 24:1022-1028
Robinson, Tara M; Prince, Gabrielle T; Thoburn, Chris et al. (2018) Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. Leuk Lymphoma 59:2801-2811
Grant, Melanie L; Bollard, Catherine M (2018) Cell therapies for hematological malignancies: don't forget non-gene-modified t cells! Blood Rev 32:203-224
Ghosh, Nilanjan; Ye, Xiaobu; Tsai, Hua-Ling et al. (2017) Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biol Blood Marrow Transplant 23:1903-1909
Majzner, Robbie G; Mogri, Huzefa; Varadhan, Ravi et al. (2017) Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biol Blood Marrow Transplant 23:612-617
Alonso, Salvador; Jones, Richard J; Ghiaur, Gabriel (2017) Retinoic acid, CYP26, and drug resistance in the stem cell niche. Exp Hematol 54:17-25
Cruz, Conrad R Y; Bollard, Catherine M (2017) Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells. Curr Drug Targets 18:271-280
Fuchs, Ephraim Joseph (2017) Related haploidentical donors are a better choice than matched unrelated donors: Point. Blood Adv 1:397-400
Kanakry, Christopher G; BolaƱos-Meade, Javier; Kasamon, Yvette L et al. (2017) Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood 129:1389-1393

Showing the most recent 10 out of 456 publications